Skip to main content

Table 2 Molecular Alterations in tumors of metastatic colorectal cancer patients

From: A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

Pt number

Sex

Age

Previous adjuvant CT

Type of adjuvant CT

Previous regimen for metastatic disease

Tumor Best response

Time to progression (weeks)

KRAS exon 1

EGFR exon13

EGFR copy Number (FISH)

Responders

       

1

F

70

0

 

-

PR

10

Wild-type

R521K

high polysomy

2

M

62

0

 

Folfirinox

PR

94*

Wild-type

 

trisomy

3

F

56

0

 

Folfiri, Folfox

PR

9

Wild-type

 

high polysomy

4

M

37

0

 

Folfiri, Folfox, xelox

PR

44

Wild-type

 

low polysomy

5

F

44

0

 

Folfiri, Folfiri

PR

33

Wild-type

R521K

disomy

6

F

54

1

LV5FU

Folfiri

PR

67

Gly13Asp

 

disomy

7

F

52

1

Fufol

Folfirinox, Folfiri, LV5FU-mitomycine

PR

42

Gly12Asp

R521K

disomy

8

M

56

0

 

Foflfox

PR

25

Wild-type

 

disomy

9

M

66

1

Fufol

Folfiri, Folfox

PR

24*

Wild-type

R521K

trisomy

Non-responders

       

10

F

68

0

 

Folfiri, Xeloda, Xelox

SD

17

Wild-type

R521K

trisomy

11

F

74

1

LV5FU

Folfiri

SD

10

Gly12Val

 

disomy

12

M

61

0

 

Folfirinox

SD

18

Gly13Asp

R521K

disomy

13

F

71

0

 

Xelox Avastin-Xeliri

SD

15

Gly12Asp

 

disomy

14

M

59

0

 

LV5FU, Folfiri, Folfox

SD

24

Gly12Cys

R521K

trisomy

15

M

71

0

 

Folfox, Irinotecan

SD

14

Wild-type

 

disomy

16

F

60

1

Fufol

Folfiri, Folfox, Cape, LV5FU

SD

17

Wild-type

 

trisomy

17

M

65

0

 

Folfirinox, Folfiri

SD

18

Wild-type

 

low polysomy

18

M

66

0

 

Folfiri

SD

17

Wild-type

R521K

disomy

19

F

45

0

 

Folfox, Xelox

SD

17

Wild-type

R521K

NE

20

F

42

0

 

Folfirinox

SD

21

Gly12Asp

R521K

trisomy

21

M

62

1

Folfox

Xeliri

SD

36

Gly13Asp

R521K

disomy

22

M

58

1

Folfiri

Xelox, Xeliri

PD

NA

Gly13Asp

 

disomy

23

M

75

1

Xelox

Xeliri

PD

NA

Wild-type

 

trisomy

24

M

81

0

 

Xelox, Folfiri

PD

NA

Gly12Val

 

disomy

25

F

55

0

 

Xelox Avastin-Xeliri

PD

NA

Gly12Asp

 

disomy

26

M

60

1

LV5FU

Folfiri, Folfiri, Folfox

PD

NA

Wild-type

 

NE

27

M

59

0

 

Folfiri, Folfiri/Folfox, Folfox

PD

NA

Gly12Asp

 

NE

28

F

58

1

LV5FU

Folfiri, Xelox

PD

NA

Gly12Asp

 

disomy

29

M

51

0

 

Folfox, Folfiri

PD

NA

Wild-type

 

disomy

30

F

66

0

 

Folfiri, Xelox

PD

NA

Wild-type

R521K

trisomy

31

F

56

0

 

-

PD

NA

Wild-type

 

disomy

32

F

78

0

 

Folfox, Folfiri, Cape

PD

NA

Gly12Val

 

disomy

  1. F = female, M = Male, Folfox = oxaliplatin, fluorouracil, and folinic acid; Xelox = capecitabine, oxaliplatin; Folfiri = irinotecan, fluorouracil, and folinic acid; Xeliri = Capecitabine, irinotecan; Folfirinox = oxaliplatin, irinotecan, fluorouracil, and folinic acid; LV5FU = infusional FU and folinic acid; Fufol = bolus fluorouracil and folinic acid; PR = partial response. SD = stable disease. PD = progressive disease. R521K = point substitution G→A on exon 13 EGFR resulting in the amino acid substitution Arg to Lys in position 521. NA = not applicable. NE = not evaluable.